Reply from the authors: Myasthenic crises in COVID-19

Affiliations

¹ Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA.
² Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA; Department of Biochemistry, Microbiology and Immunology, Wayne State University, Detroit, MI 48201, USA.
³ Henry Ford Health Systems, Wyandotte, MI 48192, USA.
⁴ Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA. Electronic address: dzutshi@med.wayne.edu.

Comment

Maryam J Syed et al. J Neurol Sci. 2020.

. 2020 Oct 15:417:117061.

doi: 10.1016/j.jns.2020.117061. Epub 2020 Jul 27.

¹ Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA.
² Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA; Department of Biochemistry, Microbiology and Immunology, Wayne State University, Detroit, MI 48201, USA.
³ Henry Ford Health Systems, Wyandotte, MI 48192, USA.
⁴ Department of Neurology, Wayne State University and Detroit Medical Center, Detroit, MI 48201, USA. Electronic address: dzutshi@med.wayne.edu.

No abstract available

Comment on

Myasthenic crisis in COVID-19.
Delly F, Syed MJ, Lisak RP, Zutshi D. Delly F, et al. J Neurol Sci. 2020 Jul 15;414:116888. doi: 10.1016/j.jns.2020.116888. Epub 2020 May 6. J Neurol Sci. 2020. PMID: 32413767 Free PMC article.

1. Jani-Acsadi A., Lisak R.P. Myasthenic crisis: guidelines for prevention and treatment. J. Neurol. Sci. 2007;261(1–2):127–133. doi: 10.1016/j.jns.2007.04.045. - DOI - PubMed
1. Lisak R., Selwa J. Immune-mediated disease of the neuromuscular junction. In: Bibiana Bielekova G.B., Lisak Robert P., editors. Neuroimmunology. vol. 94. Oxford University Press; New York, NY: 2019. pp. 131–176. Contemporary Neurology Series. - DOI
1. Administration USFD FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-agai... [cited 2020 7/17/2020]. Available from:
1. Ramaswamy S.B., Govindarajan R. COVID-19 in refractory myasthenia gravis- a case report of successful outcome. J Neuromuscul Dis. 2020;7(3):361–364. doi: 10.3233/JND-200520. - DOI - PMC - PubMed
1. Anand P., Slama M.C.C., Kaku M., Ong C., Cervantes-Arslanian A.M., Zhou L. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020 doi: 10.1002/mus.26918. - DOI - PMC - PubMed